Turning Point Therapeutics Appoints Dr. Robert Xin as Senior Vice President of Clinical Development

SAN DIEGO — Turning Point Therapeutics, Inc., a clinical-stage precision oncology company developing novel drugs that address treatment resistance, today announced the appointment of Robert (Xiaohua) Xin, M.D., Ph.D., as senior vice president of clinical development.

“With our lead asset advancing toward a registration study and our pipeline assets progressing through IND enabling studies, Robert joins our team at the perfect time with excellent experience to help guide our programs,” said Athena Countouriotis, M.D., chief executive officer. “Our team is growing and with each new hire I am pleased we are attracting talented and passionate leaders, like Robert, who bring the experience and patient commitment to help ensure our continued success.”

Dr. Xin has more than 20 years of oncology drug discovery and clinical development experience in biotech and large biopharma companies for indications in solid tumors and hematologic malignancies, in a variety of therapeutic modalities. For the past 6 years, he has served in positions of increasing leadership responsibility at Pfizer, most recently as interim vice president of oncology clinical development. Before Pfizer, Dr. Xin served for 7 years at Roche/Genentech in senior oncology clinical development roles. His early career experience includes drug discovery, development and translational medicine roles at Chiron, Eli Lilly and Sugen. His extensive experience includes multiple successful drug approvals, companion diagnostic development, regulatory and clinical strategy and organizational leadership.

“The Turning Point Therapeutics team has developed an impressive pipeline of kinase inhibitors with encouraging pre-clinical and clinical results,” said Dr. Xin. “I look forward to contributing to the development of these assets and ultimately making a difference in the lives of patients who develop resistance to conventional kinase-inhibitor therapies.”

Dr. Xin earned his M.D. and M.S. in Pharmacology degrees from the Zhejiang University School of Medicine in China. In addition, he earned a Ph.D. in Cell and Molecular Physiology from the University of North Carolina at Chapel Hill School of Medicine.

About Turning Point Therapeutics Inc.

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase-naïve and pre-treated patients, and is expected to enter a registrational study in the second half of 2019. Turning Point’s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to overcome treatment resistance common in other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com.


Turning Point Therapeutics, Inc.
Jim Mazzola